| Age, years |
69.8±12.3 |
| Male |
27/45 (60.0) |
| Female |
18/45 (40.0) |
| Current smoker |
8/44 (18.2) |
| Echocardiographic characteristics |
| MR grade* |
1+ |
3/45 (6.7) |
| 2+ |
13/45 (28.9) |
| 3+ |
14/45 (31.1) |
| 4+ |
15/45 (33.3) |
| LVEDD, mm |
63 (9) |
| LVESD, mm |
54 (9) |
| LVEDVi, ml/m2
|
107 (26) |
| LVESVi, ml/m2
|
65 (24) |
| LVEF, % |
40 (9) |
| Functional characteristics |
| NYHA Class |
II |
12/45 (26.7) |
| III |
30/45 (66.7) |
| IV |
3/45 (6.7) |
| 6-minute walk distance in metres, median (IQR) |
280 (200-408) |
| EQ5D-5L quality of life scale#, median (IQR) |
0.75 (0.70-0.84) |
| EQ5D visual analogue health status score (0-100) |
52.5 (50.0-70.0) |
| EuroSCORE, % |
5.0±7.6 |
| Society of Thoracic Surgeons (STS) score, % |
3.8±3.4 |
| Cardiovascular history |
| Myocardial infarction |
17/45 (37.8) |
| CABG |
6/45 (13.3) |
| PTCA (bare metal stent or drug-eluting) |
15/45 (33.3) |
| Pacemaker/AICD |
12/45 (26.7) |
| Atrial fibrillation |
20/45 (44.4) |
| Peripheral vascular disease |
2/44 (4.5) |
| No. of hospitalisations for heart failure in last 2 years |
0.7±0.8 |
| 0 |
21/44 (47.7%) |
| 1 |
19/44 (43.2%) |
| 2 or more |
4/44 (9.1%) |
| Baseline medications |
| ACE inhibitor or ARB |
38/45 (84.4%) |
| Beta-blocker |
40/45 (88.9%) |
| Diuretic |
44/45 (97.7%) |
| * 3 patients enrolled with locally assessed MR grade of 2+ but were determined to have MR grade of 1+ by the echo core laboratory. #Using UK weighting14. |
